CDMO Recipharm and Enzymatica, a life science company specializing in products with a protective barrier, have signed a broadened contract for the manufacture of ColdZyme®.
The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing production volumes of ColdZyme. Both the facilities in Parets, Spain, and Pianezza, will be making additional investments to accommodate requirements moving forward, according to the companies.
“Signing this expanded agreement is a great example of the long-term partnerships we build with our customers. Not only are we committed to providing high quality services and ensuring we meet project requirements, but we invest to adapt in line with our customers’ needs,” said Kenth Berg, vice president, business management, Recipharm.
“Recipharm’s strong track record, extensive expertise in managing the development and manufacturing complexities of combined drug and device products, are part of the reason we have enjoyed such a successful partnership to date,” added Claus Egstrand, COO at Enzymatica.
ColdZyme is one of Enzymatica’s first products and is intended to treat and alleviate common cold. The product has already been launched in about 30 countries across three continents.
